Details:
The strategic collaboration between Cipla and SIGA will provide the Biomedical Advanced Research and Development Authority (BARDA), a U.S. Department of Health and Human Services (HHS) department, with solutions for its biothreat and public health needs.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Undisclosed
Partner/Sponsor/Collaborator: SIGA Technologies
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 23, 2021
Details:
Premas Biotech has successfully completed the milestone of obtaining clones of all three coronavirus antigens, Spike, Envelope, and Membrane (M) that they have selected for their vaccine candidate.
Lead Product(s): COVID-19 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 06, 2020